(Newswire Today) London, United Kingdom, 2007-11-13
- New analysis from Frost & Sullivan, European Peripheral Stents Market, finds that the market earned revenues of $160.7 million in 2006 and estimates this to reach $376.2 million in 2013.
The European peripheral stents market is in the developmental phase, both in terms of revenue and technology. Improved diagnosis of peripheral arterial disease, greater awareness of this condition and of available treatments will promote market expansion. Studies demonstrating the efficacy of novel product offerings will reinforce growth trends in the market.
New analysis from Frost & Sullivan (medicaldevices.frost.com), European Peripheral Stents Market, finds that the market earned revenues of $160.7 million in 2006 and estimates this to reach $376.2 million in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European Peripheral Stents Market, then send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore[.]frost.com with your full name, company name, title, telephone number and email address. Upon receipt of the above information, an overview will be sent to you by email.
"The move towards minimally invasive surgeries and the rising incidence of peripheral arterial disease has increased the need for stenting," notes Frost & Sullivan Research Analyst Sowmya Rajagopalan. "Research and innovation have been the norm in this developing market, with shortcomings in existing products being rapidly addressed to ensure their success."
At the same time, manufacturers have moved to boost revenues by developing products for new applications. The launch of dedicated below the knee (BTK) stents is the best example of the emergence of new application areas. The need to treat arterial disease in the narrow arteries lying below the knee was studied along with the drawbacks of using coronary stents for this purpose. This led to the need for dedicated stents, resulting in the development of BTK stents.
However, as the use of stents in peripheral applications is new in comparison to coronary stents, and because surgical procedures have been the gold standard for the treatment of peripheral arterial disease, the acceptance of these products has been relatively low. Moreover, a sizeable percentage of the patient base remains untreated, resulting in an under exploitation of the potential patient pool and, in turn, limiting revenues.
"There is a dearth of sufficiently trained surgeons to perform these procedures," says Rajagopalan. "The lack of training is resulting in improper stenting, thereby affecting the success of both the procedures and products."
To promote sustained market expansion, manufacturers should conduct symposiums and workshops to enhance awareness among patients and physicians about peripheral arterial disease and peripheral stents.
European Peripheral Stents Market is part of the Medical Devices Growth Partnership Services program, which also includes research in the following: European Markets for Catheters and Guidewires for Angioplasty and Angiography and European Medical Lasers Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.